Barbara Tate, Ph.D.

Barbara joined Satori in 2010. Prior to joining Satori, Barbara was in Pfizer Global Research and Development, where, as a Senior Director, she was responsible for the Alzheimer’s Disease Target Identification and Validation Unit. She was also a member of the Alzheimer’s Disease Area Strategy Team, a company-wide team responsible for developing a long-term vision for the company in this disease area. Barbara had been on the faculties of Harvard Medical School and Brown Medical School prior to joining Pfizer, working to understand the basic mechanisms of neurodegeneration and regeneration. She earned her Ph.D. in Biology from the University of Delaware and completed postdoctoral work at Harvard Medical School.